Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
1. Novartis plans to acquire Tourmaline Bio for $48 per share. 2. Tourmaline's drug pacibekitug targets inflammation in cardiovascular disease. 3. Phase 2 trial results show significant reduction in inflammation markers. 4. Acquisition expected to close in Q4 2025, subject to conditions. 5. Novartis aims to enhance its cardiovascular portfolio with this asset.